Skip to content

Author

Ling-Feng Tang

We have 3 of 32 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk

Background: Triple-negative breast cancer (TNBC) is exceptionally aggressive, with a high recurrence rate, resistance to chemotherapy, and a tendency to metastasize. The long non-coding RNA growth arrest-specific 5 (GAS5) is associated with TNBC progression; however, the specific mechanism still requires further explor...

Jun-Ze Du, Xin He, Ling-Feng Tang et al. · 0 citations
Open access Jul 2026

VASN Enhances IGF2BP3 Stability via USP10 Deubiquitination to Promote Triple-negative Breast Cancer Paclitaxel Resistance

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective treatment options, and paclitaxel resistance remains a major clinical challenge. This study investigated the role of VASN in mediating paclitaxel resistance in TNBC by integrating transcriptomic and single-cell RNA sequencing data from publ...

Haoqi Liu, Zexiu Lu, Mao-Shan Chen et al. · 0 citations
Open access Jul 2026

GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer.

GPR19 functions as a novel oncogenic driver and clinically relevant biomarker in breast cancer, particularly in TP53-mutant and TNBC subsets, and was significantly upregulated in TP53-mutant breast cancer, primary tumors, and especially TNBC.

Jihan Qiu, Cheng Tian, Hanzhi Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.